Immunovia initiates search for a new CFO to support commercialization in the USA
Immunovia (IMMNOV: Nasdaq Stockholm), a pancreatic cancer diagnostics company, announced it is searching for a new Chief Financial Officer as it prepares to commercialize its test in the USA in the second half of 2025. The company seeks a CFO with diagnostics or med tech operating experience, US industry contacts, and expertise in communicating with global capital markets.
Current CFO Karin Almqvist Liwendahl will step down at the end of Q1 2025, after contributing to streamlining the organization, lowering operating costs, and reducing cash burn over the past three years. In the interim, CEO Jeff Borcherding and the finance team will assume financial leadership responsibilities.
Immunovia focuses on developing blood-based testing for early pancreatic cancer detection. The company estimates that 1.8 million high-risk individuals in the USA could benefit from annual surveillance testing, making it the world's largest market for pancreatic cancer detection.
Immunovia (IMMNOV: Nasdaq Stockholm), un'azienda specializzata nella diagnostica del cancro pancreatico, ha annunciato di essere alla ricerca di un nuovo Chief Financial Officer mentre si prepara a commercializzare il suo test negli Stati Uniti nella seconda metà del 2025. L'azienda cerca un CFO con esperienza operativa nel settore diagnostico o della tecnologia medica, contatti nell'industria statunitense e competenze nella comunicazione con i mercati dei capitali globali.
Il CFO attuale, Karin Almqvist Liwendahl, si dimetterà alla fine del primo trimestre del 2025, dopo aver contribuito a snellire l'organizzazione, ridurre i costi operativi e diminuire il consumo di liquidità negli ultimi tre anni. Nel frattempo, il CEO Jeff Borcherding e il team finanziario assumeranno le responsabilità di leadership finanziaria.
Immunovia si concentra sullo sviluppo di test basati sul sangue per la rilevazione precoce del cancro pancreatico. L'azienda stima che 1,8 milioni di individui ad alto rischio negli Stati Uniti potrebbero beneficiare di test di sorveglianza annuali, rendendo questo il mercato più grande al mondo per la rilevazione del cancro pancreatico.
Immunovia (IMMNOV: Nasdaq Stockholm), una empresa de diagnóstico del cáncer de páncreas, anunció que está buscando un nuevo Director Financiero mientras se prepara para comercializar su prueba en los EE. UU. en la segunda mitad de 2025. La empresa busca un CFO con experiencia operativa en diagnóstico o tecnología médica, contactos en la industria estadounidense y experiencia en comunicación con los mercados de capital globales.
La actual CFO, Karin Almqvist Liwendahl, dejará su cargo al final del primer trimestre de 2025, después de contribuir a optimizar la organización, reducir los costos operativos y disminuir el consumo de efectivo en los últimos tres años. Mientras tanto, el CEO Jeff Borcherding y el equipo financiero asumirán las responsabilidades de liderazgo financiero.
Immunovia se centra en desarrollar pruebas basadas en sangre para la detección temprana del cáncer de páncreas. La empresa estima que 1,8 millones de personas de alto riesgo en los EE. UU. podrían beneficiarse de pruebas de vigilancia anuales, convirtiéndolo en el mercado más grande del mundo para la detección del cáncer de páncreas.
Immunovia (IMMNOV: Nasdaq Stockholm), 췌장암 진단 회사가 2025년 하반기에 미국에서 테스트를 상용화할 준비를 하면서 새로운 최고재무책임자(CFO)를 찾고 있다고 발표했습니다. 이 회사는 진단 또는 의료 기술 운영 경험, 미국 산업 연락처, 글로벌 자본 시장과의 커뮤니케이션 전문성을 갖춘 CFO를 찾고 있습니다.
현 CFO인 Karin Almqvist Liwendahl은 2025년 1분기 말에 물러날 예정이며, 지난 3년 동안 조직을 간소화하고 운영 비용을 낮추며 현금 소모를 줄이는 데 기여했습니다. 그동안 CEO Jeff Borcherding과 재무 팀이 재무 리더십 책임을 맡게 됩니다.
Immunovia는 조기 췌장암 발견을 위한 혈액 기반 검사를 개발하는 데 집중하고 있습니다. 이 회사는 미국에서 180만 명의 고위험 개인이 연간 감시 테스트의 혜택을 받을 수 있을 것으로 추정하고 있으며, 이는 췌장암 발견을 위한 세계 최대 시장입니다.
Immunovia (IMMNOV: Nasdaq Stockholm), une entreprise spécialisée dans le diagnostic du cancer du pancréas, a annoncé qu'elle était à la recherche d'un nouveau directeur financier alors qu'elle se prépare à commercialiser son test aux États-Unis au cours de la seconde moitié de 2025. L'entreprise recherche un CFO ayant une expérience opérationnelle dans le domaine du diagnostic ou de la technologie médicale, des contacts dans l'industrie américaine et une expertise en communication avec les marchés de capitaux mondiaux.
La CFO actuelle, Karin Almqvist Liwendahl, quittera ses fonctions à la fin du premier trimestre 2025, après avoir contribué à rationaliser l'organisation, à réduire les coûts d'exploitation et à diminuer la consommation de liquidités au cours des trois dernières années. En attendant, le PDG Jeff Borcherding et l'équipe financière assumeront les responsabilités de leadership financier.
Immunovia se concentre sur le développement de tests basés sur le sang pour la détection précoce du cancer du pancréas. L'entreprise estime que 1,8 million de personnes à haut risque aux États-Unis pourraient bénéficier de tests de surveillance annuels, faisant de ce marché le plus important au monde pour la détection du cancer du pancréas.
Immunovia (IMMNOV: Nasdaq Stockholm), ein Unternehmen für die Diagnostik von Bauchspeicheldrüsenkrebs, hat bekannt gegeben, dass es einen neuen Chief Financial Officer sucht, während es sich darauf vorbereitet, seinen Test in der zweiten Hälfte des Jahres 2025 in den USA zu kommerzialisieren. Das Unternehmen sucht einen CFO mit Erfahrung im Bereich Diagnostik oder Medizintechnik, Kontakten in der US-Industrie und Fachkenntnissen in der Kommunikation mit globalen Kapitalmärkten.
Die derzeitige CFO, Karin Almqvist Liwendahl, wird Ende des ersten Quartals 2025 zurücktreten, nachdem sie dazu beigetragen hat, die Organisation zu straffen, die Betriebskosten zu senken und den Cashburn in den letzten drei Jahren zu reduzieren. In der Zwischenzeit werden CEO Jeff Borcherding und das Finanzteam die finanziellen Führungsverantwortlichkeiten übernehmen.
Immunovia konzentriert sich auf die Entwicklung von blutbasierten Tests zur frühzeitigen Erkennung von Bauchspeicheldrüsenkrebs. Das Unternehmen schätzt, dass 1,8 Millionen hochriskante Personen in den USA von jährlichen Überwachungstests profitieren könnten, was den weltweit größten Markt für die Erkennung von Bauchspeicheldrüsenkrebs darstellt.
- Planned commercialization of pancreatic cancer test in H2 2025
- Large addressable market with 1.8 million high-risk individuals in the USA
- Successful reduction in operating costs and cash burn
- Loss of experienced CFO during critical pre-commercialization phase
- Interim gap in dedicated financial leadership until new CFO appointment
As Immunovia transitions to commercializing its test in the second half of 2025, the company's financial leadership needs are changing. The launch of Immunovia's pancreatic cancer test in the
With this move, Karin Almqvist Liwendahl, will be stepping down as CFO of Immunovia.
"Karin has played an important role in the transformation of Immunovia over the last three years," says Jeff Borcherding, CEO and President of Immunovia. "Karin has helped us streamline the organization, lower operating costs, and reduce our cash burn. I appreciate all she has done and wish Karin the best in her next endeavor."
Karin will continue to fulfill her responsibilities as CFO until the end of the first quarter of 2025. Immunovia has initiated the recruitment process for a successor. In the interim period, financial leadership responsibilities will be assumed by Jeff Borcherding and Immunovia finance team members.
For further information, please contact
Jeff Borcherding, CEO
jeff.borcherding@immunovia.com
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
For more information, please visit www.immunovia.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/immunovia-initiates-search-for-a-new-cfo-to-support-commercialization-in-the-usa-302382458.html
SOURCE Immunovia AB
FAQ
When will Immunovia (IMMNOV) launch its pancreatic cancer test in the USA?
How large is Immunovia's potential market in the USA for pancreatic cancer testing?
When is Immunovia's current CFO Karin Almqvist Liwendahl stepping down?
Who will manage Immunovia's financial responsibilities after the current CFO leaves?
What type of CFO candidate is Immunovia (IMMNOV) looking for?
